Jenna Butner, MD
Addiction Medicine · New Haven, CTNPI 1316258775
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 67.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $26,858 and has fallen 99.8% since, to $65 in 2021. Among addiction medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $363.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Gilead$8K
- Janssen Products, LP$100
- Novo Nordisk$77
- Johnson & Johnson$40
- Alkermes, Inc.$38
- plus $15 from 1 others
What the payments were for
- Consulting fees$6,73825%
- Speaking & faculty fees$14,97056%
- Travel & lodging$3,49213%
- Food & beverage$1,6356%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $18,252 |
| Gilead | 22 | $8,413 |
| Janssen Products, LP | 1 | $100 |
| Novo Nordisk | 4 | $77 |
| Johnson & Johnson | 4 | $40 |
| Alkermes, Inc. | 2 | $38 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,934 in reported general payments places this provider in the 95th percentile of 28 addiction medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 16 | $73,209 |
| RelistorMethylnaltrexone Bromide | 17 | $71,421 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $55,894 |
| Chlorzoxazone | 13 | $10,609 |
| RestasisCyclosporine | 11 | $6,646 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 15 | $6,600 |
| LinzessLinaclotide | 13 | $6,456 |
| Megestrol Acetate | 15 | $2,427 |
| Diclofenac Sodium | 16 | $2,087 |
| Lidocaine | 15 | $1,937 |
| SynthroidLevothyroxine Sodium | 16 | $704 |
| Methadone Hcl | 25 | $535 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $372 |
| EndocetOxycodone Hcl/Acetaminophen | 12 | $317 |
| ErythromycinErythromycin Base In Ethanol | 15 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $8,413 | $55,89415 claims |
| AbbVieRestasis, Linzess, Synthroid | $18,252 | $13,80740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 addiction medicine providers in Connecticut.
Other addiction medicine in New Haven
- Brian KarsifNew Haven$528
- Bridget MartellNew Haven$135
- Erica HeimanNew Haven$0
- Cara BorelliNew Haven$0
- Paul JoudreyNew Haven$0
- Sami HamdanNew Haven$0
- Ayaz MadraswallaPutnam$14K
- Neal LakritzEnfield$3K
- Mahboob AslamRocky Hill$2K
- Thomas DefantiNorth Stonington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.